Abstract: The present invention relates to improved epicutaneous administration methods for vaccination of a subject. In particular, the present invention discloses the use of an antigen for epicutaneous immunization, wherein the antigen is administered by epicutaneous application with a skin patch device in combination with an epidermal skin treatment.

Abstract: The present invention relates to the epicutaneous vaccination against RSV vaccination with a skin patch device loaded with a particle exposing an RSV-F protein, a variant or a fragment thereof.

Abstract: The present invention relates to improved epicutaneous administration methods for vaccination of a subject. In particular, the present invention discloses the use of an antigen for epicutaneous immunization, wherein the antigen is administered by epicutaneous application with a skin patch device in combination with an epidermal skin treatment.

Abstract: The present invention relates to improved methods for vaccination of a subject. Particularly, the present invention discloses the use of skin antigen application to amplify and improve a pre-existing immunity against a selected pathogen in a subject. The present invention discloses the use of skin application in combination with conventional vaccination or priming for improved immunization or vaccination of a subject against a selected pathogen.

Abstract: The present invention relates to compositions and methods for improving a subject condition by epicutaneous immunobalancing. The invention shows that particular regulatory T cells can be induced and maintained in a subject by epicutaneous treatment, thereby causing a substantial improvement in a subject condition. The invention may be used in a preventive context, to improve the immunobalance of a subject and avoid the onset or development of diseases, as well as in a therapeutic context, to improve a subject recovery. The invention is particularly suitable to prevent or treat a proliferative or autoimmune disease. The invention may be used in any mammalian subject, preferably in human subjects, including children and adults.

Abstract: The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.

Abstract: The present invention relates to the treatment of haemophilia. More specifically, the invention relates to a new method of inducing an immune tolerance against at least one blood factor used to treat haemophilia through the epicutaneous route by application of a skin patch device comprising a blood factor in order to continue haemophilia treatment. The present invention also relates to the skin patch device containing Factor VIII.

Abstract: The present invention relates to the treatment of EE. More specifically, the invention relates to a new method of treating EE through the epicutaneous route. In particular, the method of the invention comprises applying to the skin of the subject a skin patch device, comprising a composition, under conditions allowing a contact between said composition and the skin. The present invention also relates to the skin patch device and to a use of the skin patch device in the manufacture of a composition for treating eosinophilic esophagitis in a subject.

Abstract: The present invention relates to compositions and methods for preventing allergy in a subject. Particularly, the present invention relates to epicutaneous prevention of allergies in children. The invention also relates to compositions for use in such methods, as well as their manufacture. The invention may be used to cause protection against any allergy, particularly food or respiratory allergies.

Abstract: The present invention relates to the treatment of EE. More specifically, the invention relates to a new method of treating EE through the epicutaneous route. In particular, the method of the invention comprises applying to the skin of the subject a skin patch device, comprising a composition, under conditions allowing a contact between said composition and the skin. The present invention also relates to the skin patch device and to a use of the skin patch device in the manufacture of a composition for treating eosinophilic esophagitis in a subject.

Abstract: The present invention describes a new method for progressive desensitization of a subject to groundnut. More specifically, the invention relates to the immunotherapeutic method for increasing groundnut tolerance in an allergic subject using epicutaneous administration. The present invention is also relative to the use of a skin patch device for progressive desensitization of a subject to groundnut.

Abstract: The present invention relates to the treatment of eczema. More specifically, the invention relates to a new method of treating eczema through the epicutaneous route. In particular, the method of the invention comprises applying to a non eczematous area of the skin of the subject a skin patch device, comprising a composition, under conditions allowing a contact between said composition and the skin. The present invention also relates to the skin patch device.

Abstract: The present invention describes a new method for progressive desensitization of a subject to groundnut. More specifically, the invention relates to the immunotherapeutic method for increasing groundnut tolerance in an allergic subject using epicutaneous administration. The present invention is also relative to the use of a skin patch device for progressive desensitization of a subject to groundnut.